EnteroMedics Stock Surges On VBLOC® Results (NASDAQ:ETRM)

EnteroMedics Inc. (NASDAQ:ETRM)

While Gold and Crude Oil sectors experience gains in the financial markets, take a look at EnteroMedics Inc. ticker symbol ETRM. The Stock surged +41.61% Up 0.57 generating over 16.4 million shares in the financial markets Tuesday December 3, 2013 11:41AM EST. EnteroMedics is a developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. What’s pushing the stock Up in today’s financial markets you ask? The answer is VBLOC®.

Today the Company (www.enteromedics.com) announced VBLOC® 18 month efficacy and safety results from its 5 year ReCharge Pivotal Trial of VBLOC® vagal blocking therapy for the treatment of obesity.  Studies indicated that patients in the VBLOC group (n=117), reached excess weight loss of 25%, or 10% total body weight loss, compared to 12% excess weight loss, or 4% total body weight loss for sham control group patients (n=42). The anti-obesity therapeutics global  market  is expected to grow at compound annual growth rate of 9.3% over the next 5 years reaching around $1.8 billion by 2018. Stock market analyst can only speculate on EnteroMedics delivery as they continue to strengthen their balance sheet.

****

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

With the passage of the Affordable Care Act, take a look at Conatus Pharmaceuticals Inc. ticker symbol CNAT. The Stock surged +21.33% Up 1.31 generating above 934 thousand shares in the financial markets Tuesday December 3, 2013 11:58AM EST. Conatus Pharmaceuticals is a biotechnology company targeting the development and commercialization of novel medicines to treat liver disease. What’s moving the stock Up in today’s financial markets you ask? The answer is Emricasan.

The Company (www.conatuspharma.com) announced yesterday that the FDA has allowed Orphan Drug Designation to Conatus Pharmaceuticals drug candidate emricasan  for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The liver diseases therapeutics global  market  is expected to grow at compound annual growth rate of 8.6% over the next 5 years reaching around $10.9 billion by 2018. Don’t forget, that Conatus Pharmaceuticals net loss figures of $3.3 million concerning Q3 2013 have experienced improvement when compared to the year prior net loss figures of $2.6 million.   

****

Crown Equity Holdings Inc. (OTCMKTS:CRWE)

While the financial market analyst across the globe speculate on what Janet Yellen will bring next year for the Wall Street, let’s refocus our attention towards Crown Equity Holdings Inc. ticker symbol CRWE. Crown Equity Holdings specializes in a vast array of network services in reference to website distribution and development, investor relations, human resources, video streaming through CRWETube (http://crwetube.com/), and advertisement. The stock has gexperienced +66.67% uptrend in the stock market concerning its 1 year performance . If we were in a game of poker, the chip up would be the Company (http://crownequityholdings.com) has founded iB2B Global.

The United States ecommerce market expects to make around $262.3 billion in sales this year concerning internet conducted transactions. iB2B Global is a global B2B trade online directory for wholesale and retailers. To view iB2B Global short form business plan visit URL (http://crownequityholdings.com/extras/iB2BGlobal_business_plan.pdf) via the internet. iB2B Global expects to achieve $10 to $15 million in total EBITA by the end of their third year.  

****

Baxano Surgical, Inc. (NASDAQ:BAXS)

As investors speculate on the global market concerning medical instruments and when to get in, check out Baxano Surgical, Inc. ticker symbol BAXS. The stock surged +15.53% Up 0.16 generating above 749 thousand shares in the financial markets Tuesday December 3, 2013 12:37PM EST. Baxano Surgical is a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The U.S. orthopedic market expects to reach around $4.2 billion within the next 3 years.

Today, the Company (http://baxanosurgical.com) announced the execution of a comprehensive financing that includes securing a credit facility of up to $15.0 million with Hercules Technology Growth Capital, Inc. and entering into a stock purchase agreement for up to $7.0 million with Lincoln Park Capital Fund, LLC. As Baxano Surgical continues with their growth strategy, stock market  investors can only imagine what increased asset value will bring towards this Company.     

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/